MacroGenics initiated at BTIG

MacroGenics assumed with a Buy at BTIG. BTIG analyst Thomas Shrader assumed MacroGenics with a Buy rating and a price target if $30, saying he is positive on its DART and TRIDENT multi-functional antibodies programs and its Fc Optimization technology that “allows antibodies to interact more strongly with immune effector cells that resolve antibody-antigen complexes”. The analyst contends that while the company’s monoclonal antibodies, or mAb, development space is “crowded”, MacroGenics offers “nearly two decades of tough won experience” and over two years of cash runway to give its “deep pipeline” multiple opportunities to “turn heads”.
https://thefly.com/landingPageNews.php?id=2787819